Bank of New York Mellon’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.2M | Buy |
760,629
+24,071
| +3% | +$530K | ﹤0.01% | 1652 |
|
|
2026
Q1 | $16.4M | Sell |
736,558
-15,427
| -2% | -$369K | ﹤0.01% | 1649 |
|
|
2025
Q4 | $20.1M | Sell |
751,985
-43,880
| -6% | -$1.05M | ﹤0.01% | 1536 |
|
|
2025
Q3 | $17M | Sell |
795,865
-10,513
| -1% | -$249K | ﹤0.01% | 1630 |
|
|
2025
Q2 | $17.4M | Buy |
806,378
+1,988
| +0.2% | +$37K | ﹤0.01% | 1602 |
|
|
2025
Q1 | $13.4M | Buy |
804,390
+394,640
| +96% | +$7.17M | ﹤0.01% | 1714 |
|
|
2024
Q4 | $7.52M | Sell |
409,750
-23,116
| -5% | -$373K | ﹤0.01% | 2073 |
|
|
2024
Q3 | $6.66M | Sell |
432,866
-92,700
| -18% | -$1.55M | ﹤0.01% | 2141 |
|
|
2024
Q2 | $8.54M | Buy |
525,566
+22,513
| +4% | +$363K | ﹤0.01% | 2043 |
|
|
2024
Q1 | $9.3M | Sell |
503,053
-47,859
| -9% | -$1.19M | ﹤0.01% | 1996 |
|
|
2023
Q4 | $17.2M | Sell |
550,912
-14,979
| -3% | -$358K | ﹤0.01% | 1670 |
|
|
2023
Q3 | $11.8M | Sell |
565,891
-1,981
| -0.3% | -$53.8K | ﹤0.01% | 1845 |
|
|
2023
Q2 | $13.6M | Sell |
567,872
-4,298
| -0.8% | -$95.5K | ﹤0.01% | 1779 |
|
|
2023
Q1 | $10.8M | Sell |
572,170
-12,542
| -2% | -$239K | ﹤0.01% | 1900 |
|
|
2022
Q4 | $9.31M | Buy |
584,712
+53,195
| +10% | +$831K | ﹤0.01% | 1979 |
|
|
2022
Q3 | $8.7M | Buy |
531,517
+36,708
| +7% | +$594K | ﹤0.01% | 1974 |
|
|
2022
Q2 | $6.97M | Sell |
494,809
-14,980
| -3% | -$280K | ﹤0.01% | 2142 |
|
|
2022
Q1 | $12.3M | Sell |
509,789
-15,539
| -3% | -$376K | ﹤0.01% | 1961 |
|
|
2021
Q4 | $12.3M | Buy |
525,328
+4,051
| +0.8% | +$81.5K | ﹤0.01% | 1989 |
|
|
2021
Q3 | $8.66M | Buy |
521,277
+20,473
| +4% | +$395K | ﹤0.01% | 2209 |
|
|
2021
Q2 | $12.2M | Buy |
500,804
+70,281
| +16% | +$1.59M | ﹤0.01% | 2022 |
|
|
2021
Q1 | $11.1M | Sell |
430,523
-46,653
| -10% | -$2.05M | ﹤0.01% | 2032 |
|
|
2020
Q4 | $25.5M | Buy |
477,176
+67,848
| +17% | +$3.37M | 0.01% | 1502 |
|
|
2020
Q3 | $16.9M | Sell |
409,328
-16,755
| -4% | -$724K | ﹤0.01% | 1565 |
|
|
2020
Q2 | $20.7M | Sell |
426,083
-80,521
| -16% | -$3.87M | 0.01% | 1421 |
|
|
2020
Q1 | $21.4M | Sell |
506,604
-20,756
| -4% | -$855K | 0.01% | 1252 |
|
|
2019
Q4 | $22.6M | Buy |
527,360
+29,545
| +6% | +$1.29M | 0.01% | 1497 |
|
|
2019
Q3 | $17.9M | Buy |
497,815
+21,105
| +4% | +$640K | ﹤0.01% | 1596 |
|
|
2019
Q2 | $12.7M | Sell |
476,710
-33,303
| -7% | -$851K | ﹤0.01% | 1818 |
|
|
2019
Q1 | $13.7M | Buy |
510,013
+21,937
| +4% | +$512K | ﹤0.01% | 1799 |
|
|
2018
Q4 | $7.89M | Buy |
488,076
+7,750
| +2% | +$150K | ﹤0.01% | 2045 |
|
|
2018
Q3 | $9.97M | Buy |
480,326
+39,518
| +9% | +$622K | ﹤0.01% | 2028 |
|
|
2018
Q2 | $6.73M | Buy |
440,808
+25,768
| +6% | +$459K | ﹤0.01% | 2231 |
|
|
2018
Q1 | $9.33M | Sell |
415,040
-41,442
| -9% | -$1.15M | ﹤0.01% | 2014 |
|
|
2017
Q4 | $13.7M | Buy |
456,482
+3,786
| +0.8% | +$121K | ﹤0.01% | 1824 |
|
|
2017
Q3 | $17.1M | Buy |
452,696
+32,418
| +8% | +$1.05M | ﹤0.01% | 1662 |
|
|
2017
Q2 | $11.7M | Buy |
420,278
+23,632
| +6% | +$704K | ﹤0.01% | 1872 |
|
|
2017
Q1 | $13.6M | Buy |
396,646
+21,191
| +6% | +$748K | ﹤0.01% | 1783 |
|
|
2016
Q4 | $10.8M | Buy |
375,455
+12,255
| +3% | +$324K | ﹤0.01% | 1922 |
|
|
2016
Q3 | $11.6M | Sell |
363,200
-41,744
| -10% | -$1.42M | ﹤0.01% | 1799 |
|
|
2016
Q2 | $13.1M | Sell |
404,944
-22,281
| -5% | -$746K | ﹤0.01% | 1693 |
|
|
2016
Q1 | $11.9M | Sell |
427,225
-387,454
| -48% | -$8.45M | ﹤0.01% | 1724 |
|
|
2015
Q4 | $29M | Sell |
814,679
-243,888
| -23% | -$8.59M | 0.01% | 1150 |
|
|
2015
Q3 | $35M | Buy |
1,058,567
+47,359
| +5% | +$1.97M | 0.01% | 1056 |
|
|
2015
Q2 | $42.3M | Sell |
1,011,208
-155,856
| -13% | -$6.03M | 0.01% | 996 |
|
|
2015
Q1 | $38M | Sell |
1,167,064
-744,076
| -39% | -$25.6M | 0.01% | 1055 |
|
|
2014
Q4 | $60.7M | Sell |
1,911,140
-290,309
| -13% | -$8.23M | 0.02% | 798 |
|
|
2014
Q3 | $54.5M | Buy |
2,201,449
+1,766,720
| +406% | +$41.3M | 0.01% | 820 |
|
|
2014
Q2 | $9.82M | Sell |
434,729
-6,866
| -2% | -$143K | ﹤0.01% | 1944 |
|
|
2014
Q1 | $10.7M | Buy |
441,595
+18,596
| +4% | +$470K | ﹤0.01% | 1863 |
|
|
2013
Q4 | $10.6M | Buy |
422,999
+2,690
| +0.6% | +$63.5K | ﹤0.01% | 1854 |
|
|
2013
Q3 | $11.5M | Buy |
420,309
+17,606
| +4% | +$368K | ﹤0.01% | 1758 |
|
|
2013
Q2 | $7.31M | Buy |
+402,703
| New | +$5.55M | ﹤0.01% | 1963 |
|
Other funds holding ACAD
N
PAM
RHJA
GT
Bank of New York Mellon's ACAD Position: Q2 2026 in Review
Bank of New York Mellon increased its Acadia Pharmaceuticals (ACAD) stake by 3.3% in Q2 2026, buying an estimated $530K and bringing the position to 760,629 shares worth $19.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1652.
Bank of New York Mellon first reported a position in ACAD in Q2 2013 and has held it in 53 quarters since. The position peaked at $60.7M in Q4 2014. 159 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.
- Bank of New York Mellon held 760,629 shares of Acadia Pharmaceuticals worth $19.2M as of Q2 2026.
- Bank of New York Mellon bought 24,071 Acadia Pharmaceuticals shares in Q2 2026, an estimated $530K.
- Acadia Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1652 holding.
- Bank of New York Mellon first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Acadia Pharmaceuticals position peaked at $60.7M in Q4 2014.
- 159 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.